Skip to content

Author

M. Yotsukura

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

A randomized phase III study optimizing adjuvant osimertinib for resected EGFR-mutant stage II-III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01).

The OASIS trial [Japan Cancer Treatment Optimization group (JACTOP)-01] is a multicenter, randomized, open-label, phase III study optimizing adjuvant osimertinib therapy for patients with completely resected, epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) stage II-III non-squamous non-small...

Ken Onodera, Yoshinori Okada, Y. Kudo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.